HR and neoplasm: Moreover a 7.5% chance of undetected true negative would be lower than the false negative rate currently considered acceptable for SLN (< 10%).42,43 This result was confirmed to be independent from patients’ age, tumor IHC subtype (HR+/HER2−, HER2+, TNBC), clinical stage at diagnosis, PST (NACT or NET, with or without anti-HER2 agents), radiologic response to PST, and SLN study methods [conventional or One-Step Nucleic Acid (OSNA)].